43,247 results match your criteria Cytopathology [Journal]


Haploinsufficiency of UNC13D increases the risk of lymphoma.

Cancer 2019 Feb 13. Epub 2019 Feb 13.

Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden.

Background: Experimental models have demonstrated that immune surveillance by cytotoxic lymphocytes can protect from spontaneous neoplasms and cancer. In humans, defective lymphocyte cytotoxicity is associated with the development of hemophagocytic lymphohistiocytosis, a hyperinflammatory syndrome. However, to the best of the authors' knowledge, the degree to which human lymphocyte cytotoxicity protects from cancer remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32011DOI Listing
February 2019

Impact of healthy lifestyles on cancer risk in the Chinese population.

Cancer 2019 Feb 12. Epub 2019 Feb 12.

Key Laboratory of Cardiovascular Epidemiology & Department of Epidemiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Background: Although cancer has become one of the leading health burdens, to the authors' knowledge, evidence regarding its relationship with a healthy lifestyle in the Chinese population remains limited.

Methods: The authors evaluated the association between clustering of healthy lifestyle factors and cancer risk using 3 prospective cohort studies with 101,208 Chinese adults from the general population. Hazard ratios (HRs) and corresponding 95% confidential intervals (95% CIs) related to healthy lifestyle factors were calculated using Cox proportional hazard models, and population-attributable risk percentages were estimated further. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31971DOI Listing
February 2019

Reply to Tumor-associated macrophages: "Good cop-bad cop".

Cancer 2019 Feb 12. Epub 2019 Feb 12.

Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32015DOI Listing
February 2019

The distribution and prevalence of human papillomavirus in women in mainland China.

Cancer 2019 Feb 12. Epub 2019 Feb 12.

Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China.

We conducted a systematic review of the epidemiology of high-risk human papillomavirus (HPV) infections in mainland Chinese women to provide a general profile for the application and subsequent effectiveness evaluation of HPV vaccines. The PubMed, Web of Science, Medline (Ovid), China National Knowledge Infrastructure, and Wanfang databases were used for the literature search. The epidemiological studies published from January 2000 to June 2018 on high-risk HPVs in mainland Chinese women were investigated to systematically evaluate their epidemiological status. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.32003
Publisher Site
http://dx.doi.org/10.1002/cncr.32003DOI Listing
February 2019
1 Read

Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy.

Cancer 2019 Feb 12. Epub 2019 Feb 12.

Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Background: The current study was performed to assess the efficacy of surveillance imaging in patients with head and neck cancer (HNC) who are treated definitively with radiotherapy.

Methods: Eligible patients included those with a demonstrable disease-free interval (≥1 follow-up imaging procedure without evidence of disease and a subsequent visit/imaging procedure) who underwent treatment of HNC from 2000 through 2010.

Results: A total of 1508 patients were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31983DOI Listing
February 2019

The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening.

Cancer 2019 Feb 12. Epub 2019 Feb 12.

Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32008DOI Listing
February 2019

Targeting autophagy using natural compounds for cancer prevention and therapy.

Cancer 2019 Feb 12. Epub 2019 Feb 12.

Lake Erie College of Osteopathic Medicine, Bradenton, Florida.

Autophagy, also known as macroautophagy, is a tightly regulated process involved in the stress responses, such as starvation. It is a vacuolar, lysosomal pathway for the degradation of damaged proteins and organelles in eukaryotic cells. Autophagy also plays a key role in various tissue processes and immune responses and in the regulation of inflammation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31978DOI Listing
February 2019

Radiation therapy treatment facility and overall survival in the adjuvant setting for locally advanced head and neck squamous cell carcinoma.

Cancer 2019 Feb 12. Epub 2019 Feb 12.

Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut.

Background: Treatment at high-volume surgical facilities (HVSFs) provides a survival benefit for patients with head and neck squamous cell carcinomas (HNSCCs); however, it is unknown what role postoperative radiation therapy (PORT) plays in achieving the improved outcomes.

Methods: From the National Cancer Database, 6844 patients with locally advanced invasive HNSCCs of the oral cavity, oropharynx, larynx, and hypopharynx who underwent definitive surgery with PORT between 2004 and 2013 were identified. HVSFs were those in the top percentile for annual case volume during this period. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32001DOI Listing
February 2019

Tumor-associated macrophages: "Good cop-bad cop".

Cancer 2019 Feb 12. Epub 2019 Feb 12.

Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32016DOI Listing
February 2019

Cyclooxygenase-2 in gastrointestinal malignancies.

Cancer 2019 Feb 12. Epub 2019 Feb 12.

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

Cyclooxygenase (COX) is an enzyme complex that plays an important role in the conversion of arachidonic acid to prostaglandins. Prostaglandins are essential modulators of signal transduction pathways, which contribute to the metastatic properties of gastrointestinal (GI) malignancies. Although COX-1 is constitutively active, COX-2 is upregulated by cytokines, growth factors, and mitogen. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32010DOI Listing
February 2019

Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy: A psychological perspective.

Cancer 2019 Feb 12. Epub 2019 Feb 12.

Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31980DOI Listing
February 2019

Breast cancer deaths averted over 3 decades.

Cancer 2019 Feb 11. Epub 2019 Feb 11.

Department of Radiology and Rogel Cancer Center, University of Michigan Health System, Ann Arbor, Michigan.

Background: From 1975 to 1990, female breast cancer mortality rates in the United States increased by 0.4% per year. Since 1990, breast cancer mortality rates have fallen between 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31954DOI Listing
February 2019

Plasmacytoid morphology of poorly differentiated thyroid carcinoma: diagnostic approach with brief review of literature.

Cytopathology 2019 Feb 3. Epub 2019 Feb 3.

Department of Pathology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry.

Poorly differentiated thyroid carcinoma (PDTC) is an uncommon neoplasm of thyroid accounting for 4-7% of all thyroid neoplasm's (1) that are rarely diagnosed accurately on cytology. Medullary thyroid carcinoma (MTC) is the most frequent primary thyroid neoplasm manifesting with plasmacytoid morphology possibly followed by Hürthle neoplasm (HCN) because of their high incidence compared to other subtypes of malignancy. The plasmacytoid morphology in other primary thyroid neoplasms is uncommon and distinguishing such neoplasm's from MTC is crucial for the clinical management of patients presenting with neoplastic thyroid nodules. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cyt.12681DOI Listing
February 2019
1 Read

Impact of patient choice and hospital competition on patient outcomes after prostate cancer surgery: A national population-based study.

Cancer 2019 Feb 1. Epub 2019 Feb 1.

Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Background: Policies that encourage patient choice and hospital competition have been introduced across several countries with the purpose of improving the quality of health care services. The objective of the current national cohort study was to analyze the correlation between choice and competition on outcomes after cancer surgery using prostate cancer as a case study.

Methods: The analyses included all men who underwent prostate cancer surgery in the United Kingdom between 2008 and 2011 (n = 12,925). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31987DOI Listing
February 2019

Change in health-related quality of life in older women after diagnosis of a small breast cancer.

Cancer 2019 Feb 1. Epub 2019 Feb 1.

Department of Surgery, Johns Hopkins Hospital and School of Medicine, Baltimore, Maryland.

Background: Screening mammography reduces breast cancer mortality at the cost of frequent false-positive results that lead to unnecessary medical procedures, and the treatment of indolent breast cancers that would never threaten life or health. Earlier diagnosis generally permits less disruptive treatment, but it is possible that even the diagnosis of a very small breast cancer could significantly adversely impact health-related quality of life (HRQOL) in older women.

Methods: The authors compared changes in HRQOL measured by either the Medical Outcomes Study 36-Item Short Form (SF-36) or the Veterans Rand 12-item Health Survey (VR-12) between 198 women diagnosed with in situ or invasive breast cancer measuring ≤1 cm and 36,814 matched controls using the National Cancer Institute's Surveillance, Epidemiology, and End Results cancer registry linked with the Medicare Health Outcomes Survey. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31993
Publisher Site
http://dx.doi.org/10.1002/cncr.31993DOI Listing
February 2019
2 Reads

Primary care provider-reported involvement in breast cancer treatment decisions.

Cancer 2019 Feb 1. Epub 2019 Feb 1.

Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.

Background: Treatment decisions for patients with early-stage breast cancer often involve discussions with multiple oncology providers. However, the extent to which primary care providers (PCPs) are involved in initial treatment decisions remains unknown.

Methods: A stratified random sample of PCPs identified by newly diagnosed patients with early-stage breast cancer from the Georgia and Los Angeles Surveillance, Epidemiology, and End Results registries were surveyed (n = 517; a 61% response rate). Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31998
Publisher Site
http://dx.doi.org/10.1002/cncr.31998DOI Listing
February 2019
2 Reads

A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients.

Cancer 2019 Feb 1. Epub 2019 Feb 1.

Winship Cancer Institute of Emory University, Atlanta, Georgia.

Background: Despite effective therapies, outcomes for diffuse large B-cell lymphoma (DLCBL) remain heterogeneous in older individuals due to comorbid diseases and variations in disease biology.

Methods: Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, the authors conducted a multistate survival analysis of 11,780 patients with DLBCL who were aged ≥65 years at the time of diagnosis (2002-2009). Cox proportional hazards models were used to specify the impact of prognostic factors on overall survival and cause-specific deaths, and the Aalen-Johansen estimator was used to project the course of DLBCL over time with or without standard therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31981DOI Listing
February 2019
1 Read

Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.

Cancer 2019 Feb 1. Epub 2019 Feb 1.

Division of Hematology/Oncology, University of Chicago, Chicago, Illinois.

Background: Dual translocation of MYC and BCL2 or the dual overexpression of these proteins in patients with aggressive B-cell lymphomas (termed double-hit lymphoma [DHL] and double-expressor lymphoma [DEL], respectively) have poor outcomes after chemoimmunotherapy with the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Retrospective reports have suggested improved outcomes with dose-intensified regimens. In the current study, the authors conducted a phase 1 study to evaluate the feasibility, toxicity, and preliminary efficacy of adding lenalidomide to dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin with rituximab (DA-EPOCH-R) in patients with DHL and DEL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31877DOI Listing
February 2019
1 Read

Lasting effects of cancer and its treatment on employment and finances in adolescent and young adult cancer survivors.

Cancer 2019 Feb 1. Epub 2019 Feb 1.

Fred Hutchinson Cancer Research Center, Seattle, Washington.

Background: The impact of cancer and its treatment on employment and financial burden in adolescents/young adults (AYAs) is not fully known.

Methods: Eligibility for this cross-sectional study of AYA cancer survivors included the diagnosis of a malignancy between ages 18 and 39 years and survey completion within 1 to 5 years from diagnosis and ≥1 year after therapy completion. Participants were selected randomly from the tumor registries of 7 participating sites and completed an online patient-reported outcomes survey to assess employment and financial concerns. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31985DOI Listing
February 2019
2 Reads

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial.

Cancer 2019 Feb 1. Epub 2019 Feb 1.

GSK, Wavre, Belgium.

Background: The adjuvanted recombinant zoster vaccine (RZV) has demonstrated >90% efficacy against herpes zoster in adults ≥50 years of age and 68% efficacy in autologous hematopoietic stem cell transplant recipients ≥18 years of age. We report the immunogenicity and safety of RZV administered to patients with solid tumors (STs) before or at the start of a chemotherapy cycle.

Method: In this phase 2/3 observer-blind, multicenter study (NCT01798056), patients with STs who were ≥18 years of age were randomized (1:1) to receive 2 doses of RZV or placebo 1-2 months apart and stratified (4:1) according to the timing of the first dose with respect to the start of a chemotherapy cycle (first vaccination 8-30 days before the start or at the start [±1 day] of a chemotherapy cycle). Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31909
Publisher Site
http://dx.doi.org/10.1002/cncr.31909DOI Listing
February 2019
14 Reads

The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.

Cancer 2019 Feb 1. Epub 2019 Feb 1.

Department of Hematology, Local Social Health Authority (ASST) Spedali Civili Brescia, Brescia, Italy.

Background: Stopping tyrosine kinase inhibitor (TKI) treatment has become a realistic and safe objective for patients who have chronic myeloid leukemia (CML). Both a sustained deep molecular response (sDMR) and the lack of a molecular recurrence after TKI discontinuation are required to reach a durable treatment-free remission (TFR).

Methods: The potential predictive role of BCR-ABL transcripts in attaining an sDMR and a TFR was analyzed in a strictly consecutive, unselected series of 194 patients who were diagnosed and treated with TKIs at the authors' center. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31977
Publisher Site
http://dx.doi.org/10.1002/cncr.31977DOI Listing
February 2019
2 Reads

Reply to Unexpectedly low rates of neuropsychiatric adverse effects associated with mefloquine repurposed for the treatment of glioblastoma.

Cancer 2019 Feb 1. Epub 2019 Feb 1.

Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31960DOI Listing
February 2019

A randomized study to improve care for young women with breast cancer at community and academic medical oncology practices in the United States: The Young and Strong study.

Cancer 2019 Feb 1. Epub 2019 Feb 1.

Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts.

Background: The authors conducted a cluster randomized study to determine the effect of an exportable educational intervention for young women with breast cancer (YWI) on improving care.

Methods: Sites were randomized 1:1 to the YWI or a contact time control physical activity intervention (PAI) stratified by academic or community site. Up to 15 women aged ≤45 years with newly diagnosed breast cancer were enrolled at each of 14 academic sites and 10 were enrolled at each of 40 community sites. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31984DOI Listing
February 2019

Unexpectedly low rates of neuropsychiatric adverse effects associated with mefloquine repurposed for the treatment of glioblastoma.

Cancer 2019 Feb 1. Epub 2019 Feb 1.

The Quinism Foundation, White River Junction, Vermont.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31961DOI Listing
February 2019

Treatment costs pose major financial stress for patients.

Authors:
Carrie Printz

Cancer 2019 Feb;125(4):495

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31990DOI Listing
February 2019

Factors influencing prostate cancer treatment decisions for African American and white men.

Cancer 2019 Jan 29. Epub 2019 Jan 29.

University of North Carolina School of Medicine, Chapel Hill, North Carolina.

Background: Prostate cancer racial disparities in mortality outcomes are the largest in all of oncology, and less aggressive treatment received by African American (AA) patients versus white patients is likely a contributing factor. However, the reasons underlying the differences in treatment are unclear.

Methods: This study examined a prospective, population-based cohort of 1170 men with newly diagnosed nonmetastatic prostate cancer enrolled from 2011 to 2013 before treatment throughout North Carolina. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31932DOI Listing
January 2019
1 Read

Choice of first-line therapy in metastatic melanoma.

Cancer 2019 Jan 29. Epub 2019 Jan 29.

Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31774DOI Listing
January 2019

Avoiding chemotherapy prescribing errors: Analysis and innovative strategies.

Cancer 2019 Jan 29. Epub 2019 Jan 29.

Department of Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Background: At Freiburg University Medical Center, chemotherapy prescriptions are processed via a computerized physician order entry (CPOE) tool and clinically checked by a designated chemotherapy surveillance team. Any error detected is reported instantly, corrected, and prospectively recorded. The objective of the current study was to gain insight into the causes, potential consequences, and future preventability of chemotherapy prescribing errors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31950DOI Listing
January 2019

How much of US health care spending provides direct care or benefit to patients?

Cancer 2019 Jan 29. Epub 2019 Jan 29.

College of Medicine, University of South Alabama, Mobile, Alabama.

Plans to optimize health care in the United States highlight the high cost but rarely explore opportunities for redirecting resources within the existing system to increase access to care while lowering spending. This analysis indicates that, of the total national health care expenditures of $3.21 trillion in 2015, only $1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31865DOI Listing
January 2019

The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.

Cancer 2019 Jan 29. Epub 2019 Jan 29.

University of Washington Medical Center, Seattle, Washington.

Background: The role of autologous stem cell transplantation (ASCT) in the first complete remission (CR1) of peripheral T-cell lymphomas (PTCLs) is not well defined. This study analyzed the impact of ASCT on the clinical outcomes of patients with newly diagnosed PTCL in CR1.

Methods: Patients with newly diagnosed, histologically confirmed, aggressive PTCL were prospectively enrolled into the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) study, and those in CR1 were included in this analysis. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31861
Publisher Site
http://dx.doi.org/10.1002/cncr.31861DOI Listing
January 2019
6 Reads

Growth hormone deficiency and neurocognitive function in adult survivors of childhood acute lymphoblastic leukemia.

Cancer 2019 Jan 28. Epub 2019 Jan 28.

Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee.

Background: The impact of growth hormone deficiency (GHD) on neurocognitive function is poorly understood in survivors of childhood acute lymphoblastic leukemia (ALL). This study examined the contribution of GHD to functional outcomes while adjusting for cranial radiation therapy (CRT).

Methods: Adult survivors of ALL (N = 571; 49% female; mean age, 37. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31975DOI Listing
January 2019
1 Read

Meaningful differences and validity for the NCCN/FACT-P symptom index: An analysis of the ALSYMPCA data.

Cancer 2019 Jan 28. Epub 2019 Jan 28.

Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Background: The Functional Assessment of Cancer Therapy-Prostate (FACT-P) and the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index-17 (NFPSI-17) are 2 commonly used measures for patient-reported outcomes in prostate cancer trials. Their use may be enhanced by a better understanding of how change scores on the measures should be interpreted.

Methods: Using data from the phase 3 Alpharadin in Symptomatic Prostate Cancer Patients trial, this study estimated important change scores on the FACT-P and the NFPSI-17 via a combination of distribution- and anchor-based methods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31973DOI Listing
January 2019

A randomized trial of immediate versus delayed survivorship care plan receipt on patient satisfaction and knowledge of diagnosis and treatment.

Cancer 2019 Jan 28. Epub 2019 Jan 28.

The University of Wisconsin-Madison Carbone Cancer Center, Madison, Wisconsin.

Background: Survivorship care plans (SCPs) and care-planning sessions have been recommended for over a decade, yet evidence for their benefit remains mixed. In a randomized trial, changes in survivor knowledge and satisfaction before and after the receipt of an SCP were assessed.

Methods: Patients with breast cancer who had completed curative-intent treatment were randomized to immediate versus delayed receipt of an individualized SCP. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31875
Publisher Site
http://dx.doi.org/10.1002/cncr.31875DOI Listing
January 2019
6 Reads

A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.

Cancer 2019 Jan 28. Epub 2019 Jan 28.

The Angeles Clinic and Research Institute, Los Angeles, California.

Background: Glembatumumab vedotin is an antibody-drug conjugate that produced preliminary clinical activity against advanced melanoma in a phase 1 dose-escalation trial. The objective of the current study was to investigate further the antitumor activity of glembatumumab vedotin at the recommended phase 2 dose in heavily pretreated patients with melanoma.

Methods: This single-arm, phase 2 study enrolled patients with stage IV melanoma who were refractory to checkpoint inhibition and to B-raf proto-oncogene, serine/threonine kinase (BRAF)/mitogen-activated protein kinase kinase (MEK) inhibition (in the presence of a BRAF valine mutation at codon 600). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31892DOI Listing
January 2019
4 Reads

Cytotechnologists' education and work in Finland.

Authors:
Eeva Liikanen

Cytopathology 2019 Jan 25. Epub 2019 Jan 25.

Biomedical Laboratory Science, Tampere University of Applied Sciences, Tampere, Finland.

Objective: The aim of this study was to survey the work that cytotechnologists carry out in Finland.

Methods: An electronic questionnaire was planned with the Board of the Finnish Association of Cytotechnologists and an email containing the link was sent to all 107 of its members in January 2018. It included 17 questions on their age and work experience, education and work. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cyt.12680DOI Listing
January 2019
9 Reads

Borderline resectable pancreatic cancer-At the crossroads of precision medicine.

Cancer 2019 Jan 23. Epub 2019 Jan 23.

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31936DOI Listing
January 2019

Application of positron emission tomography imaging to personalize esophagogastric cancer care.

Cancer 2019 Jan 22. Epub 2019 Jan 22.

Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31940DOI Listing
January 2019

Assessment and management of cognitive changes in patients with cancer.

Cancer 2019 Jan 22. Epub 2019 Jan 22.

Department of Psychiatry, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31905DOI Listing
January 2019
4.889 Impact Factor

Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia.

Cancer 2019 Jan 22. Epub 2019 Jan 22.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Background: DFP-10917, a deoxycytidine nucleoside analogue, has a unique mechanism of action resulting in leukemic cell death when administered for prolonged periods at low doses. The current phase 1/2 study investigated the safety, maximum tolerated dose, and evidence of antileukemic activity for DFP-10917 administered by 7-day or 14-day continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia (AML).

Methods: In the phase 1 dose escalation portion of the study, patients were administered DFP-10917 by 7-day continuous intravenous infusion plus 21-day rest (stage 1) or 14-day continuous intravenous infusion plus 14-day rest (stage 2). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31923DOI Listing
January 2019

Black women less likely to adhere to hormone therapy for breast cancer.

Authors:
Carrie Printz

Cancer 2019 Feb;125(3):331

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31970DOI Listing
February 2019
2 Reads

Management of cytological material for ancillary studies: Still an issue one decade later?

Authors:
Fernando Schmitt

Cytopathology 2019 Jan;30(1):5-6

Institute of Molecular Pathology and Immunology of Porto University (IPATIMUP), Medical Faculty of Porto University, Porto, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cyt.12668DOI Listing
January 2019
1 Read

Medical financial hardship among cancer survivors in the United States.

Cancer 2019 Jan 21. Epub 2019 Jan 21.

Surveillance and Health Services Research Program, American Cancer Society, Atlanta, Georgia.

Background: The current study examined medical financial hardship in cancer survivors and those without a cancer history in the United States.

Methods: The 2013 to 2016 National Health Interview Survey was used to identify cancer survivors (stratified by ages 18-49 years [1424 survivors], ages 50-64 years [2916 survivors], and ages ≥65 years [6014 survivors]) and individuals without a cancer history (ages 18-64 years [66,951 individuals], ages 50-64 years [31,741 individuals], and ages ≥65 years [25,744 individuals]). Medical financial hardship was categorized into 3 domains: 1) material (eg, problems paying medical bills); 2) psychological (eg, worrying about paying medical bills); and 3) behavioral (eg, delaying/forgoing care due to cost). Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31913
Publisher Site
http://dx.doi.org/10.1002/cncr.31913DOI Listing
January 2019
10 Reads

Ensuring quality in cervical screening programmes based on molecular HPV testing.

Cytopathology 2019 Jan 18. Epub 2019 Jan 18.

National Virus Reference Laboratory, University College Dublin, Belfield, Dublin 4, Ireland.

The increased use of HPV testing within cervical screening programmes necessarily brings about changes to the laboratory services which are required to support them. A crucial element of such services is to demonstrate initial and ongoing quality of the test (and associated processes). In this review we outline some of the quality-considerations and challenges with an emphasis on the laboratory including assay and platform validation, internal quality control selection and strengths and weaknesses of external quality assurance schemes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cyt.12679DOI Listing
January 2019
1 Read

Who should get a contralateral prophylactic mastectomy for breast cancer?

Cancer 2019 Jan 15. Epub 2019 Jan 15.

Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31915
Publisher Site
http://dx.doi.org/10.1002/cncr.31915DOI Listing
January 2019
7 Reads